Follow
Policy
Policy is a statement of intent or set of plans intended to achieve a rational goal by a specific organization.
-
NOV 20, 2013 | 10:00 AM
2013 has proven to be a year of paradigmatic shifts in molecular diagnostics reimbursement policy. In this session, we will review and analyze these key policy and payment developments and di...Speaker: Nicole LittmannOCT 17, 2013 | 11:00 AMC.E. CREDITS
Curative therapy for metastatic disease in solid malignancies remains frustratingly elusive due to the long recognized problem of tumor cell heterogeneity and emergence of treatment resistant...Speaker: George Poste, DVM, DSc, PhDOCT 16, 2013 | 10:00 AMC.E. CREDITS
The current paradigm of detecting established cancer (often too late) and treating routinely with cytotoxic drugs is beginning to change. Advanced technologies such as whole genome sequencin...Speaker: Anna Barker, PhDAUG 22, 2013 | 5:00 PMC.E. CREDITS
Malignancies caused by so-called Type I chemical and biological carcinogens provide important opportunities studying early events in cancer development, providing essential information for de...Speaker: Prof. Patrick Tan, MD, PhDPresented at: Genetics and Genomics Virtual Event Series 2013
AUG 22, 2013 | 3:00 PMC.E. CREDITS
The use of ultrahigh throughput diagnostic tests that determine genetic sequence variation to guide patient care is rapidly expanding, fueled by the enormous growth in sequencing platform dev...AUG 22, 2013 | 2:00 PM
The role of the human genome in normal and patho-biology is crucial. Applied in cancer care and in a variety of unknown disorder settings, it can provide key insights and crucial diagnostic/p...AUG 15, 2013 | 9:00 AM
Recent studies show a large prevalence of Vitamin D deficiency and insufficiency in populations of all ages. Concerns about excess supplementation and toxicity have emerged as a result. Th...
NOV 20, 2013 | 10:00 AM
2013 has proven to be a year of paradigmatic shifts in molecular diagnostics reimbursement policy. In this session, we will review and analyze these key policy and payment developments and di...
Speaker:
Nicole Littmann
OCT 17, 2013 | 11:00 AM
C.E. CREDITS
Curative therapy for metastatic disease in solid malignancies remains frustratingly elusive due to the long recognized problem of tumor cell heterogeneity and emergence of treatment resistant...
Speaker:
George Poste, DVM, DSc, PhD
OCT 16, 2013 | 10:00 AM
C.E. CREDITS
The current paradigm of detecting established cancer (often too late) and treating routinely with cytotoxic drugs is beginning to change. Advanced technologies such as whole genome sequencin...
Speaker:
Anna Barker, PhD
AUG 22, 2013 | 5:00 PM
C.E. CREDITS
Malignancies caused by so-called Type I chemical and biological carcinogens provide important opportunities studying early events in cancer development, providing essential information for de...
Speaker:
Prof. Patrick Tan, MD, PhD
Presented at: Genetics and Genomics Virtual Event Series 2013
AUG 22, 2013 | 3:00 PM
C.E. CREDITS
The use of ultrahigh throughput diagnostic tests that determine genetic sequence variation to guide patient care is rapidly expanding, fueled by the enormous growth in sequencing platform dev...
AUG 22, 2013 | 2:00 PM
The role of the human genome in normal and patho-biology is crucial. Applied in cancer care and in a variety of unknown disorder settings, it can provide key insights and crucial diagnostic/p...
AUG 15, 2013 | 9:00 AM
Recent studies show a large prevalence of Vitamin D deficiency and insufficiency in populations of all ages. Concerns about excess supplementation and toxicity have emerged as a result. Th...